Why Genetic Testing And Advocacy Matter In Multiple Myeloma – Dr. Shaina Rozell

31 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this segment, Dr. Shaina Rozell highlights why genetic testing and patient advocacy in multiple myeloma are critical for improving outcomes. She explains how understanding cytogenetics in multiple myeloma and monitoring minimal residual disease (MRD) guide treatment decisions and identify high-risk multiple myeloma patients who may need more aggressive therapies.

Dr. Rozell also discusses the importance of exploring every available treatment option, from stem cell transplant in multiple myeloma to newer therapies like CAR T therapy in multiple myeloma, CAR T cell therapy, and bispecific antibodies in multiple myeloma. She stresses that informed patients asking the right questions play a powerful role in shaping care and gaining access to the latest advancements.

What you’ll get to know in this segment:
▶ Why cytogenetics and MRD testing matter in tailoring multiple myeloma treatment
▶ How high-risk multiple myeloma impacts therapy choices and survival outcomes
▶ The evolving role of stem cell transplant, CAR T therapy, and bispecific antibodies in modern myeloma treatment
▶ Why patient advocacy is essential in navigating multiple myeloma diagnosis and care decisions
▶ How being proactive can expand access to clinical trials and novel therapies

While there is still no definitive multiple myeloma cure, empowering patients with knowledge and emphasizing patient advocacy in multiple myeloma ensures better decisions, stronger care partnerships, and access to the most effective treatment options available.

#multiplemyeloma #myeloma #cancer #hematology #patientadvocacy #oncology
Categoria
Oncology
Commenta per primo questo video.

Prossimo